Compounds specific to adenosine A 3 receptor and uses thereof

Details Compounds specific to adenosine A 3 receptor and uses thereof Compounds specific to adenosine A 3 receptor and uses thereof

2007-01-09

2007-01-09

Wilson, James O. (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S256000, C514S257000, C514S258100, C544S245000, C544S253000, C544S278000, C544S279000, C544S280000

Reexamination Certificate

active

09728616

ABSTRACT:
This invention pertains to compounds which specifically inhibit the adenosine A3receptor and the use of these compounds to treat a disease associated with A3adenosine receptor in a subject, comprising administering to the subject a therapeutically effective amount of the compounds.

REFERENCES:
patent: 3037980 (1962-06-01), Hitchings et al.
patent: 3910913 (1975-10-01), Kim et al.
patent: 5296484 (1994-03-01), Coghlan et al.
patent: 5409930 (1995-04-01), Spada et al.
patent: 5516894 (1996-05-01), Reppert
patent: 5580870 (1996-12-01), Barker et al.
patent: 5639913 (1997-06-01), Lidor et al.
patent: 5646130 (1997-07-01), Shi
patent: 5646156 (1997-07-01), Jacobson et al.
patent: 5681941 (1997-10-01), Cook et al.
patent: 5710158 (1998-01-01), Myers et al.
patent: 5714493 (1998-02-01), Myers et al.
patent: 5721237 (1998-02-01), Myers et al.
patent: 5747498 (1998-05-01), Schnur et al.
patent: 5780450 (1998-07-01), Shade
patent: 5780481 (1998-07-01), Jacobson et al.
patent: 5834609 (1998-11-01), Horne et al.
patent: 5877218 (1999-03-01), Herzig et al.
patent: 5877221 (1999-03-01), Cohen et al.
patent: 5880159 (1999-03-01), Herzig et al.
patent: 5914349 (1999-06-01), Cohen et al.
patent: 5962458 (1999-10-01), Lohmann et al.
patent: 5994408 (1999-11-01), Cohen et al.
patent: 6103899 (2000-08-01), Horne et al.
patent: 6680322 (2004-01-01), Castelhano et al.
patent: 6686366 (2004-02-01), Castelhano et al.
patent: 2002/0028782 (2002-03-01), Castelhano et al.
patent: 2002/0058667 (2002-05-01), Castelhano et al.
patent: 2003/0036545 (2003-02-01), Castelhano et al.
patent: 2003/0045536 (2003-03-01), Castelhano et al.
patent: 2003/0073708 (2003-04-01), Castelhano et al.
patent: 2003/0139427 (2003-07-01), Castelhano et al.
patent: 3145287 (1983-05-01), None
patent: 0322242 (1989-06-01), None
patent: 0514540 (1992-11-01), None
patent: 0682027 (1995-11-01), None
patent: 0729758 (1996-04-01), None
patent: 0729758 (1996-09-01), None
patent: 0773023 (1997-05-01), None
patent: 915303 (1963-01-01), None
patent: 157280 (1986-02-01), None
patent: 9291089 (1999-05-01), None
patent: WO 9320078 (1993-10-01), None
patent: WO 9413676 (1994-06-01), None
patent: WO9417090 (1994-08-01), None
patent: WO 9424136 (1994-10-01), None
patent: WO9511681 (1995-05-01), None
patent: WO 9518617 (1995-07-01), None
patent: WO 9519774 (1995-07-01), None
patent: WO 9519970 (1995-07-01), None
patent: WO9520597 (1995-08-01), None
patent: WO 9619478 (1996-06-01), None
patent: WO 9702266 (1997-01-01), None
patent: WO 9705138 (1997-02-01), None
patent: WO 9733879 (1997-09-01), None
patent: WO 9807726 (1998-02-01), None
patent: WO 9808382 (1998-03-01), None
patent: WO 9822465 (1998-05-01), None
patent: WO 9829397 (1998-07-01), None
patent: WO 9857651 (1998-12-01), None
patent: WO 9906053 (1999-02-01), None
patent: WO 9908460 (1999-02-01), None
patent: WO 9933815 (1999-07-01), None
patent: WO 9942093 (1999-08-01), None
patent: WO 9962518 (1999-12-01), None
patent: WO 0003741 (2000-01-01), None
Campbell et al., “Selective A1-Adenosine Receptor Antagonists Identified Using YeastSaccharomyces cerevisiaeFunctional Assays”, Bioorganic & Medicinal Chemistry Letters, vol. 9, No. 16, Aug. 16, 1999, pp. 2413-2418.
Wolff et al., “Burger's Medicinal Chemistry, 5thedition, vol. 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker et al., “Modern Pharmaceutics, 3rdedition”, Marcel Dekker, NY, 1996, pp. 596.
Kiichiro, K. et al. “Synthesis of pyrazinecarboxylic acid derivs.—(II) derivs. of 3-aminopyrazinecarboxylic acid” (1961)Yakugaku Zasshi81: 1650-1653 (Abstract only) (Exhibit 46).
Blazynski C., (1990) “Discrete Distributions of Adenosine Receptors in Mammalian Retina”,Journal of Neurochemistry, 53: 648-655 (Exhibit 28).
Braas K.M., et al., (1987) “Endogenous adenosine and adenosine receptors localized to ganglion cells of the retina”,Proceedings of the National Academy of Science, 84: 3906-3910 (Exhibit 29).
Bradford M. M., (1976) “A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding”,Anal. Biochem., 72: 248-254 (Exhibit 30).
Broach, J. R., et al., (1983) “Vectors for high level, inducible expression of cloned genes in yeast”, inExperimental Manipulation of Gene Expression. M. Inouye (ed).,Academic Press, New York, 83-117 (Exhibit 31).
Chen, Y. L., et al., (1997) “Synthesis and Oral Efficacy of a 4-(Butylethylamino)pyrrolo[2,3-d]pyramidine: A Centrally Active Corticotropin-Releasing Factor1Receptor Antagonist”,J. Med. Chem., 40: 1749-1754, (Exhibit 32).
Cheng, Y. and Prusoff, W. H. (1973) “Relationship Between The Inhibition Constant (K1) And The Concentration of Inhibitor Which Causes 50 Per Cent Inhibition (I50) Of An Enzymatic Reaction”,Biochem. Pharmacol., 22: 3099-3109 (Exhibit 33).
Christianson, T. W. et al., (1992) “Multifunctional yeast high-copy-number shuttle vectors”,Gene, 110: 119-122 (Exhibit 34).
Duzic, E. et al., (1992) “Factors Determining the Specificity of Signal Transduction by Guanine Nucleotide-binding Protein-coupled Receptors”,J. Biol. Chem., 267: 9844-9851 (Exhibit 35).
Feoktistove, I. et al., (1998) “Adenosine A2Breceptors: a novel therapeutic target in asthma?”,TiPS19: 148-153 (Exhibit 36).
Kang, Y. et al., (1990) “Effects of Expression of Mammalian Gα and Hybrid Mammalian-Yeast Gα Proteins on the Yeast Pheromone Response Signal Transduction Pathway”,Mol. Cell. Biol., 10: 2582-2590 (Exhibit 39).
Muller, C. E. and Stein, B. (1996) “Adenosine Receptor Antagonist: Structure and Potential Therapeutic Applications”,Current Pharmaceutical Design, 2: 501-530 (Exhibit 40).
Muller, C. E. (1997) “A1-Adenosine Receptor Antagonists”,Exp. Opin. Ther. Patents7(5): 419-440 (Exhibit 41).
Muller, C. E., et al., (1997) “Synthesis and Structure-Activity Relationships of 3,7-Dimethyl-1-propargylxanthine Derivatives, A2A-Selective Adenosine Receptor Antagonists”,J. Med. Chem., 40: 4396-4405 (Exhibit 42).
Nyce J. W. and Metzger J.W., (1997) “DNA antisense therapy for asthma in an animal model”,Nature, 385: 721-725 (Exhibit 43).
Pichler, H. et al. (1986) “Synthese of 7-unsubstituierten 7H-Pyrrolo[2,3-d] pyrimidines”,Liebigs Ann. Chemie., 9: 1485-1505 (Exhibit 44).
Seela, F., and Lupke, U., (1977)U. Chem. Ber., 110:1462-1469 (Exhibit 45).
Strohmeier, G. R. et al., (1995) “The A2bAdenosine Receptor Mediates cAMP Responses to Adenosine Receptor Agonists in Human Intestinal Epithelia”,J. Bio. Chem., 270: 2387-2394 (Exhibit 46).
Williams, E. F. et al., (1994) “Nucleoside transport sites in a cultured human retinal cell line established by SV-40 T antigen gene”,Current Eye Research, 13: 109-118 (Exhibit 47).
Woods, C. L. and Blazynski, C. (1991) “Characterization of Adenosine A1-receptor Binding Sites in Bovine Retinal Membranes”,Experimental Eye Research, 53: 325-331 (Exhibit 48).
Iwamura, H. et al. (1996) “Quantitative Aspects of the Receptor Binding of Cytokinin Agonists and Antagonists”J. Med. Chem., 26: 838-844 (Exhibit 72).
Jorgensen, A. et al. (1985) “Synthesis of 7H-Pyrrolo[2,3-d]pyrimidin-4-amines”Liebigs. Ann. Chem., pp. 142-148 (Exhibit 73).
Muller, E. C. et al. (1996) “Chiral Pyrrolo[2,3-d]pyrimidine and Pyrimido[4,5, -b]indole Derivatives: Structure-Activity Relationships of Potent, Highly Stereoselective A1-Adenosine Receptor Antaogonist”J. Med. Chem., 39: 2482-2491 (Exhibit 75).
Muller, C. E. et al. (1990) “7-Deaza-2-phenyl adenines: Structure-Activity Relationships of Potent A1 Selective Adenosine Receptor Antagonists”J. Med. Chem., 33: 2822-2828 (Exhibit 76).
Venugopalan, B. et al. (1998) “Synthesis of 6,7-Dimethoxypyrimido[4,5-b]—indoles as Potential Antihypertensive Agents”J. Heterocyclic Chem., 25: 1633-1639 (Exhibit 77); and.
West, R. A. et al.

Affiliated with

Also associated with

Rating

Compounds specific to adenosine A 3 receptor and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds specific to adenosine A 3 receptor and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds specific to adenosine A 3 receptor and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3753842